ACE-031 1mg: Myostatin inhibitor Peptide

ACE-031 is a soluble activin type IIB receptor (ActRIIB-Fc) fusion protein engineered to bind and neutralize myostatin and related ligands of the TGF-β superfamily. It is widely studied for its potential role in muscle growth, muscle-wasting disorders, cellular differentiation, and developmental biology within controlled research environments.

By inhibiting myostatin signaling, ACE-031 provides a powerful research tool for investigating the pathways that regulate muscle mass and tissue growth.

Scientific Background

Myostatin (GDF-8) is a natural inhibitor of muscle growth. ACE-031 is a synthetic protein designed to act as a decoy receptor, binding circulating myostatin and preventing it from attaching to its natural cellular receptor.

ACE-031 consists of:

• The extracellular domain of Activin Receptor Type IIB, and

• A human IgG1 Fc fragment (to enhance stability and half-life)

In preclinical studies, ACE-031 has been associated with:

• Increased muscle mass

• Reduced myostatin activity

• Enhanced muscle-fiber size (hypertrophy)

• Modulation of activin A and related ligands

• Effects on muscle regeneration and metabolic pathways

Because of these properties, it is frequently used in studies exploring muscle wasting, sarcopenia, cachexia, and genetic myopathies.

Research Areas of Interest

All information below is intended strictly for laboratory, scientific, and in-vitro research only.

1. Myostatin Inhibition Research

ACE-031 is a leading tool for investigating:

• Myostatin blockade mechanisms

• GDF-8 pathway biology

• Muscle growth regulation

2. Muscle Hypertrophy & Regeneration Models

Preclinical research evaluates potential effects on:

• Satellite-cell activation

• Muscle-fiber size and density

• Muscle repair following injury

3. TGF-β Signaling Pathways

Since ActRIIB interacts with multiple TGF-β family cytokines, ACE-031 is used to study:

• Activin A/B

• GDF-11

• BMP-related pathways

4. Developmental & Growth Biology

ACE-031 is of interest in studies involving:

• Musculoskeletal development

• Metabolic regulation

• Tissue remodeling

5. Comparative Myostatin Blocker Studies

ACE-031 is studied alongside:

• Follistatin 344

• Myostatin propeptide

• GDF-8 antibodies

• YK-11 (non-peptide modulator)

These findings stem from in-vitro and preclinical research models only.

Molecular Profile

• Peptide/Protein: ACE-031 (ActRIIB-Fc Fusion Protein)

• Type: Soluble Myostatin Receptor / TGF-β Ligand Trap

• Structure: Extracellular ActRIIB domain fused to human IgG1 Fc

• Molecular Weight: ~100 kDa (may vary by manufacturer)

• Form: Lyophilized protein

• Purity: ≥ 95% (protein-grade, SDS-PAGE verified)

Note: ACE-031 is a large engineered fusion protein, not a simple peptide. Laboratory versions may differ in glycosylation patterns depending on expression system.

Storage & Stability

• Store lyophilized material at –20°C

• Protect from heat, moisture, and light

• Reconstituted solutions should be used promptly or stored per laboratory guidelines

• Avoid repeated freeze-thaw cycles

  Each 3ml vial is formulated with 1mg of highly purified (>99%) lyophilized ACE-031, produced in sterile environments that meet research-grade standards. Prime Peptides validates every batch through independent laboratory testing to ensure exact molecular composition, stable peptide structure, and consistent results suitable for a wide range of experimental designs.